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Abstract: Type 2 diabetes mellitus is a metabolic disease associated with low quality of life 
and early death. The goal in diabetes treatment is to prevent these outcomes by tight glycemic 
control and minimizing vascular risk factors. So far, even intensified combination regimen 
with the traditional antidiabetes agents have failed to obtain these goals. Incretin mimetics are 
a new class of antidiabetes drugs which involve modulation of the incretin system. They bind 
to and activate glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta-cells following 
which insulin secretion and synthesis are initiated. Since the compounds have no insulinotropic 
activity at lower glucose concentrations the risk of hypoglycemia – a well-known shortcoming 
of existing antidiabetes treatments – is low. Additionally, incretin mimetics have been shown to 
be associated with beneficial effects on cardiovascular risk factors such as weight loss, decrease 
in blood pressure and changes in lipid profile. Current clinical data on the two available incretin 
mimetics, exenatide and liraglutide, are evaluated in this review, focusing on pharmacology, 
efficacy, safety and tolerability. The review is built on a systematic PubMed and Medline search 
for publications with the key words GLP-1 receptor agonist, exenatide, liraglutide and type 2 
diabetes mellitus up to January 2009.
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Introduction
Type 2 diabetes is a metabolic disease characterized by high blood glucose caused by 
an insufficiency of the pancreas to produce insulin, hyperglucagonemia and impaired 
insulin sensitivity. The typical symptoms include thirst, polyuria, recurrent infections 
and weight loss.1 However, the majority of patients do not experience symptoms and 
are diagnosed in a late stage of the disease. The etiology of type 2 diabetes is unknown; 
however, genetic and environmental factors have been linked to its development. It is 
a chronic progressive disease associated with micro- and macrovascular complica-
tions such as nephropathy, neuropathy, retinopathy and cardiovascular morbidity. 
These complications often result in low quality of life and early death. In 2000 the 
global mortality due to diabetes was estimated to be 5.2% or 2.9 million deaths.2 The 
increased mortality is mainly due to cardiovascular events. Recent estimates indicate 
that 171 million people worldwide had diabetes in 2000 and this number is projected 
to increase to 366 million by 2030.3 As a consequence, diabetes-related deaths are 
likely to increase by more than 50% in the next 10 years. In developed countries most 
people with diabetes are above 64 years of age while most people with diabetes in the 
developing countries are younger (45 to 64 years).4 The disease is equally distributed 
among sexes.3Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 156
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The goal with diabetes treatment is to improve quality of 
life and prevent early death. It is well established that tight 
glycemic control reduces the risk of microvascular disease5–7 
while recent randomized controlled trials have failed to 
show a substantial benefit on macrovascular outcomes.7–9 
These results implicate that not only glycemic control but 
also minimizing cardiovascular risk factors (high blood 
pressure, hyperlipidemia, overweight, smoking, thrombosis 
risk) through medical intervention and life-style intervention 
should be addressed in the treatment of diabetes.
The optimal goal for glycemic control is a glycosylated 
hemoglobin A1c (HbA1c) below 7%.10 In order to reach this 
  target an intensified regimen with combinations of anti-
diabetes agents is often needed. Oral agents in monotherapy 
(thiazolidinediones [TZDs], metformin, repaglinide, 
α-glucosidase inhibitors and sulfonylurea [SU] compounds) 
improve glycemic control to almost the same degree (decrease 
in HbA1c of approximately 1%).11 When combining two anti-
diabetes drugs another 1% HbA1c reduction can be obtained. 
However, with time, supplementation with subcutaneous (sc) 
injections of insulin or insulin analogues is often necessary 
in order to compensate for insulin deficiency and maintain 
an acceptable glycemic control. This is partly due to the fact 
that type 2 diabetes is a progressive disease with an almost 
linear decline in beta-cell function (probably combined with a 
decrease in beta-cell mass) over time. None of the mentioned 
antidiabetes drugs have been shown to preserve pancreatic 
beta-cell function over time and, notably, SUs have been 
shown to accelerate the apoptosis of human beta-cells.12 
Besides, the current available drugs are associated with a 
number of shortcomings: body weight increase (TZDs, SUs 
and insulin), hypoglycemia (SUs, repaglinides and insulin) 
and gastrointestinal side effects (metformin and α-glucosidase 
inhibitors).11 The limitations of the pre-existing antidiabetes 
treatments, make new medical therapies that offer improved 
efficacy and/or durability, better convenience, and an improved 
safety and tolerability profile an absolutely imperative in order 
to get more patients to glycemic goal initially and to avoid or 
delay the need for additional treatment.
Incretin hormones
The incretin hormones glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP) are intes-
tinal peptide hormones released in response to ingestion of 
meals.13 The most important effect of GLP-1 and GIP is their 
ability to potentiate glucose-induced insulin secretion from the 
pancreas – the so-called incretin effect. In healthy subjects the 
incretin effect accounts for up to 70% of the insulin secreted 
in response to glucose ingestion.14 GLP-1 is a 30-amino acid 
polypeptide processed from proglucagon in the endocrine 
L-cells distributed primarily in the mucosa of the distal part 
of the small intestine and colon. GIP is a 42-amino acid poly-
peptide released from endocrine K-cells found in the mucosa 
of the duodenum and upper jejunum.15 While GLP-1 is rapidly 
degraded (by the ubiquitous enzyme dipeptidyl peptidase-4 
(DPP-4)) in the circulation with an apparent half-life of 1 to 
1.5 minutes,16 GIP is degraded more slowly, with a half-life 
for the intact hormone of 7 minutes.17 The hormones enhance 
insulin secretion from the beginning of a meal, but has no 
insulinotropic activity at lower glucose concentrations (less 
than 4 mM); thereby not promoting hypoglycemia. GLP-1 
also enhances insulin biosynthesis and insulin gene expres-
sion. In addition, it exerts trophic and protective actions on the 
beta-cells18 and strongly inhibits pancreatic glucagon secretion 
in a glucose-dependent manner.19 In contrast, GIP has been 
shown to stimulate glucagon secretion. The hormones exhibit 
their insulinotropic effect via G-protein coupled receptors on 
the pancreatic beta-cells.20 Beside the effects on the endocrine 
pancreas, both hormones have several other functions. GLP-1 
receptors are found in various regions of the brain21 and when 
activated these are believed to promote feeling of satiety 
which in combination with GLP-1-induced inhibition of 
gastrointestinal motility (mediated through the vagus nerve22) 
reduces food intake and body weight. GLP-1 receptors are 
also found in the heart23 and most data suggest that GLP-1 
exerts protective effects on the myocardium. GLP-1 has also 
been found to reduce the postprandial rise in triglycerides 
and lower the concentration of free fatty acids in humans.24 
Finally, animal as well as human studies indicate that GLP-1 
has natriuretic and diuretic properties by modulation of renal 
Na+/H+ exchange25 – a mechanism that might serve to reduce 
blood pressure. GIP appears to have no physiological effect 
on the gastrointestinal tract, appetite or food intake, but may 
play a role in lipid26 and bone metabolism.27
Incretin hormones and type 2  
diabetes pathophysiology
In patients with type 2 diabetes the incretin effect is severely 
reduced.28,29 This pathophysiological trait is likely to play a 
central role in the inability of these patients to secrete sufficient 
amount of insulin to prevent hyperglycemia following oral 
glucose.30 Attenuated postprandial secretion31 and decreased 
insulinotropic potency of GLP-132 in combination with 
  abolished insulinotropic effect of GIP33 seem to be responsible 
for the reduced incretin effect in patients with type 2 diabetes. 
Since the insulinotropic effect of only GLP-1 (and not GIP) is Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 157
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preserved in patients with type 2 diabetes, antidiabetes treatment 
modalities based on the effect of this peptide have been 
developed. Interestingly, intravenous (iv) infusion of native 
GLP-1 is capable of normalizing blood glucose in patients 
with type 2 diabetes,34 but due to the short half-life of GLP-1, 
therapeutic administration of native GLP-1 is impractical. 
Therefore, in order to exploit the beneficial actions of GLP-1 in 
type 2 diabetes, long-acting stable receptor agonists of GLP-1 
(incretin mimetics) have been developed. In the following 
section the current clinical data on the two available incretin 
mimetics, exenatide and liraglutide, will be described.
Incretin mimetics
Exenatide, the first in this new class of drugs, was introduced to 
the market in the United States in 2005 and in Europe in 2007 
under the trade name Byetta® (Amylin Pharmaceuticals/Eli 
Lilly). Liraglutide has been introduced to the market in Europe 
July 2009 and in the United States and Japan in January 2010 
under the trade name Victoza® (Novo Nordisk). The current 
review focuses on only these two incretin mimetics.
Pharmacology
Exenatide
Exenatide was isolated from the saliva of the lizard Heloderma 
suspectum in a search for biologically active peptides.35 
Exenatide shares 53% homology with native GLP-1 (Figure 1) 
and binds to and activates GLP-1 receptors on pancreatic 
beta-cells following which insulin secretion and synthesis is 
initiated.36 Following sc administration, exenatide is rapidly 
absorbed reaching peak concentrations in approximately 
2 hours. The half-life of exenatide is approximately 2 hours, 
and after sc injection of the maximally tolerated dose, sig-
nificant elevation of exenatide in plasma may be observed for 
5 to 6 hours. Exposure is negligible after 12 hours post dose, 
explaining why twice-daily dosing is needed in order to obtain 
full effect on glycemic control.37 Exenatide is, unlike native 
GLP-1, not substantially degraded by DPP-4 but is cleared 
primarily in the kidneys by glomerular filtration38 resulting in 
a plasma half-life for the peptide of approximately 30 min-
utes after iv administration.37 Pharmacokinetics, safety and 
efficacy of exenatide have been tested in several subgroups of 
type 2 diabetes patients. In a rather small study of adolescent 
patients with type 2 diabetes, administration of exenatide 
appeared to be well tolerated;39 in a study of Japanese patients 
with type 2 diabetes the pharmacokinetics seemed to be 
similar to that of Caucasian patients40 (no racial differences 
have been reported). Lastly, age does not seem to influence 
the pharmacokinetic properties of exenatide.41
Liraglutide
Liraglutide is an acylated analogue of human GLP-1 and has 
97% sequence homology to native GLP-1 (Figure 1). The 
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Figure 1 A) The molecular structure of human GLP-1. B) The molecular structure of exenatide (gray colors indicate differences in structure from human GLP-1. C) The 
molecular structure of liraglutide (gray colors indicate changes in structure from human GLP-1).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 158
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analogue is produced using the recombinant DNA technology 
in yeast.42 It has a similar effect on the GLP-1 receptor as 
described for exenatide. A high degree of plasma protein 
  binding causes decreased susceptibility to metabolism 
by DPP-4 and the half-life following sc administration of 
  liraglutide is approximately 13 hours.43 This protracted action 
profile makes liraglutide suitable for once-daily administration. 
There are no clinically significant differences in liraglutide 
pharmacokinetics between male and female subjects, subjects 
of different race, or elderly and younger subjects.44
Efficacy
Exenatide
The clinical effects of exenatide treatment have been 
  investigated in six published, randomized, controlled trials 
with a total of 2731 patients.45 A summary of the trials 
is presented in Table 1. Exenatide as add-on therapy to 
metformin,46 SU47 or both48 showed statistically significant 
improvement in glycemic control (HbA1c reduction of 1.0% 
(baseline HbA1c: 8.2% to 8.6%) vs a minor increase of about 
0.1% in the placebo groups) and reduction in fasting plasma 
glucose (0.5 mM in the exenatide groups vs an increase 
of about 1 mM in the placebo groups). In all three studies 
(the Three Amigos) exenatide was given twice daily in two 
  different doses (of 5 and 10 µg, respectively). The changes in 
HbA1c for 10 µg exenatide are presented in Table 1. Patients 
  receiving exenatide were more likely to achieve an HbA1c less 
than 7% compared with patients receiving placebo-with the 
best results in the high-dose (10 µg) exenatide groups49.
The effect of exenatide has also been investigated with 
insulin as active control. In a 26-week study of patients 
inadequately controlled on metformin and SU in combination 
therapy, addition of exenatide induced similar reductions 
in HbA1c (1.1% from baseline HbA1c 8.2%) as addition of 
insulin glargine.50 In a 52-week study comparing twice-
daily biphasic insulin aspart and exenatide (both added to 
existing metformin and SU treatment), exenatide induced 
similar reductions in HbA1c as insulin aspart, and provided 
significantly better postprandial glucose control.51
On average the weight loss in the three studies comparing 
exenatide to placebo amounted to 1.6 kg in the exenatide-
treated patients (baseline body weight: 96 to 100 kg).46–48 
Similar results was seen in a trial comparing exenatide with 
placebo in patients treated with TZDs.52 The difference in 
body weight change was even bigger in the insulin trials. Body 
weight in the exenatide group decreased 2.3 kg; significantly 
different from an increase of 1.8 kg in the insulin glargine-
treated group.50 In the exenatide vs insulin aspart trial a 
significant between-group difference of 4.1 kg weight loss 
was found (baseline weight 86 kg (exenatide group)/83 kg 
(insulin aspart group).51 Table 1 outlines the weight loss for 
10 µg exenatide groups in the different studies.
The beneficial effects of exenatide seem to last. In an 
open-label extension of the Three Amigos studies, 3 years’ 
sustained effects were demonstrated for glycemic control and 
body weight (decrease in HbA1c of 1% and body weight of 
5.3 kg).53 An important limitation of this study, in addition to 
its open-label design, was a high drop out rate of patients (due 
to adverse events, insufficient glycemic control, patient/inves-
tigator decision, and protocol violation), only 217 out of 517 
randomized subjects completing the 3-year study period.
Only few studies have investigated the effect of exenatide 
on cardiovascular risk profile. The open-label studies with 
a 3-year follow-up found minor, but significant improve-
ments in triglycerides (12% decrease compared to baseline), 
total cholesterol (5% decrease), low density lipoproteins 
(6% decrease) and high density lipoprotein (24% increase) 
in favor of a reduced cardiovascular risk.54 A review 
  looking at exenatide vs placebo or insulin on blood pressure 
  measurements in pooled data from 6 exenatide trials, found 
that 6 months of exenatide treatment was associated with 
a significantly greater reduction in systolic blood pressure 
compared with placebo (difference of −2.8 mmHg) or insulin 
(difference of −3.7 mmHg).55 Further studies are needed to 
elucidate the exact mechanisms behind the beneficial effects 
of exenatide on the cardiovascular risk profile.
Liraglutide
The clinical effects of liraglutide treatment have been 
investigated in the LEAD (Liraglutide Effect and Action 
in Diabetes) series of phase III studies including more than 
4000 patients with type 2 diabetes. A summary of the trials 
is presented in Table 2 with changes in HbA1c of 1.8 mg 
liraglutide. In average liraglutide reduced HbA1c by 1.2% 
from a baseline of 8.2% to 8.5%. Liraglutide in monotherapy 
(52 weeks of treatment) compared with the SU glimepiride 
was evaluated in the LEAD 3 study56 using two different doses 
of liraglutide (1.2 and 1.8 mg, respectively). The proportions 
of participants reaching the target HbA1c of 7.0% or less 
were 43%, 51% and 28% in the 1.2 mg liraglutide, 1.8 mg 
liraglutide and glimepiride groups, respectively. An open-label 
one-year extension of the LEAD 3 study showed a sustained 
beneficial effect of liraglutide compared to glimepiride on 
HbA1c.57 Improved glycemic control has also been reported 
when liraglutide is given in combination with oral antidiabetes 
therapy. In the LEAD 258 different doses of liraglutide Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 159
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(0.6, 1.2 and 1.8 mg), glimepiride and placebo added to 
existing metformin treatment were evaluated, and in the 
LEAD 1 study,59 liraglutide was added to glimepiride treatment 
and compared with rosiglitazone and placebo. In the LEAD 
4 study60 liraglutide was added to metformin in combination 
with rosiglitazone. Liraglutide (1.8 mg) added to metformin 
in combination with glimepiride was compared to the active 
comparator insulin glargine (LEAD 5 study).61 A direct com-
parison between liraglutide (1.8 mg once daily) and exenatide 
(10 µg twice daily) was reported from the open-labeled LEAD 
6 study.62 Mean HbA1c reduction was significantly greater 
with liraglutide treatment than with exenatide (1.1% vs 0.8%). 
Significant differences were also seen between the two agents 
with regard to fasting plasma glucose (1.6 mM reduction 
[liraglutide] vs 0.6 mM reduction [exenatide]). Liraglutide 
also reduced postprandial glucose across the LEAD trials. 
As for exenatide, liraglutide has a significant effect on body 
weight as shown by the data for 1.8 mg liraglutide in Table 2. 
Liraglutide reduced mean body weight or was weight neutral as 
monotherapy56 and in combination with one58,59 or two60–62 oral 
antidiabetes agents compared to placebo or active comparators. 
The LEAD 662 study examined the lipid profile on exenatide 
and liraglutide. Significant greater reductions in triglycerides 
(−0.4 vs −0.2 mM) and free fatty acids (−0.17 vs −0.10 mM) 
in the liraglutide group were observed. Both compounds 
caused a significant decrease in blood pressure (systolic blood 
  pressure −2.2 mmHg and diastolic pressure −1.5 mmHg) with 
no significant differences between the two compounds.
Safety and tolerability
The major side-effects of all compounds are mild to moderate 
and transient nausea and vomiting. These side effects are dose 
dependent and decline over time.49 Other frequently reported 
side effects encompass headache and upper respiratory 
infection.41,63 The incidence of treatment-associated 
  hypoglycemia is reported to be low41,63 – apparently due to 
the glucose-dependent insulinotropic and glucagonostatic 
effects of GLP-1. However, in combination with SU the 
incidence increases, and is dependent on the dose of SU. 
In most exenatide trials minor hypoglycemic episodes are 
defined as plasma glucose 3.3 mM; in the LEAD studies 
it is defined as plasma glucose 3.1 mM. In studies using 
exenatide combined with SU a risk of minor hypoglycemic 
episodes is reported to be between 15% and 36%.49 In stud-
ies combining liraglutide with SU the risk is reported to be 
8% to 25%.64 In the exenatide/insulin glargine study 1.5% 
of patients experienced severe hypoglycemia.50 There was no 
difference between groups and the incidence was similar in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 160
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the two groups. Only one severe hypoglycemic episode was 
reported with liraglutide and glimipiride.58
Approximately 40% of exenatide-treated patients in 
long-term, placebo-controlled studies developed antibodies 
against exenatide during the initial 30 weeks of treatment.49 
Among liraglutide-treated patients up to approximately 8% 
exhibit antibodies.56,58–61 The exact impact of antibodies in 
the longer term needs to be established. Neither exenatide 
nor liraglutide is recommended during pregnancy or lactation 
due to lack of sufficient data. Exenatide should not be used 
in patients with kidney failure since it is cleared primarily 
in the kidneys by glomerular filtration41 and reports of acute 
kidney failure have been filed. No data indicate inhibition or 
induction of cytochrome P450 drug metabolizing enzymes. 
Since 2005 the US Food and Drug Administration (FDA) 
has received 170 reports on pancreatitis in exenatide-treated 
patients, and recently the FDA received reports of acute pan-
creatitis, some of which were severe cases of hemorrhagic 
or necrotizing pancreatitis in patients taking exenatide. In 
the LEAD studies a total of 9 reports of pancreatitis were 
observed, with reports of pancreatitis in both in liraglutide-, 
placebo- and active comparator-treated patients. At this point 
it is not clear whether a causal relationship between pancreati-
tis and exenatide/liraglutide exists or the cases are incidental. 
However, it is recommended to discontinue incretin mimetic 
treatment if pancreatitis is suspected.65 In carcinogenicity 
studies with liraglutide, C-cell tumors were observed in 
thyroid tissue of mice and rats. It has been suggested that the 
findings in rodents are caused by a non-genotoxic, specific 
GLP-1 receptor-mediated mechanism to which rodents are 
particularly sensitive. The relevance for humans is likely to 
be clinical insignificant, but additional studies are needed 
to clarify the potential mechanisms behind C-cell tumor 
development in GLP-1 analogue-treated patients and their 
possible clinical implications.63
Patients
Both products are parenteral solutions intended for sc 
  injection. They can be administered in the subcutis of 
the abdomen, arm or thigh. To improve gastrointestinal 
  tolerability, exenatide therapy should be initiated at 5 µg per 
dose administered twice daily for at least a month. The dose 
of exenatide can then be increased to 10 µg twice daily.41 
Liraglutide should be initiated in a dose of 0.6 mg daily. 
After at least 1 week, the dose should be increased to 1.2 mg. 
The dose can be increased to 1.8 mg to further improve 
glycemic control. Daily doses higher than 1.8 mg are not 
recommended because of side effects. Patient satisfaction 
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using exenatide has been evaluated in a couple of studies. 
The addition of exenatide to metformin and SU resulted 
in significant improvements in treatment satisfaction and 
patients’ health-related quality of life from baseline to 
26 weeks.66 The improvement was similar for patients treated 
with insulin glargine.
Liraglutide has been on the market for only a short time 
and few reports about compliance and satisfaction exist. 
In the LEAD 6 study,62 379 patients completed a diabetes 
treatment satisfaction questionnaire at baseline and week 26, 
which showed a higher satisfaction among patients on 
  liraglutide than on exenatide.
Conclusion
Incretin mimetics offer a new and interesting treatment 
  modality in diabetes. Clinical studies have shown beneficial 
effects on glycemic control, body weight, lipid profile 
and blood pressure. This could imply substantial benefit 
on macrovascular outcomes. So far the safety profile of 
  incretin mimetics is promising. The main side-effect is mild 
to moderate and transient (weeks) nausea. The frequency 
of hypoglycemia – a well-known side effect of several 
pre-existing antidiabetes treatment modalities – is low and 
occurs mainly when incretin mimetics are administered 
in combination with SU. Incretin mimetics are not yet 
  recommended in combination with insulin. Animal studies 
indicate that administration of GLP-1 receptor agonists 
is associated with beta-cell proliferation and beta-cell 
  protection, but these effects have not yet been established 
in clinical trials. Thus, future mechanistic studies and more 
long-term clinical studies are required to elucidate these 
promising outcomes. Treatment with incretin mimetics is 
also associated with unsolved problems: The reports about 
acute pancreatitis and rodent C-cell carcinomas have caused 
concerns about long-term effects, but there are as yet no 
indications of these effects in humans. These concerns, 
taken together with the relatively short overall clinical 
experience, resulted in the label “less validated” treatment 
in the recent consensus statement for the management of 
type 2 diabetes from the American Diabetes Association 
and the European Association for the Study of Diabetes. 
However, new incretin mimetics are in the pipeline of several 
pharmaceutical companies. They are all characterized by 
improved pharmacology and longer half-lives, implying 
fewer injections. The next couple of years will elucidate 
whether the incretin mimetics will become well established 
in the treatment of type 2 diabetes. The data so far are 
encouraging.
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